

Xyla, Contract Variation
Kent and Medway 057 November 2025
Classification: Official-Sensitive: Commercial



NHS Standard Contract

VARIATION AGREEMENT

Pulse Healthcare Limited t/a Xyla Type 2 Diabetes Path to Remission Kent and Medway

Atamis Contract Reference: C233468

**Atamis Business Case Ref: BC25745 & BC-
27839**

Prepared by: NHS Standard Contract Team, NHS England
england.contractshelp@nhs.net
(please do not send variation agreements to this email address)

Republished: March 2022

Publication Approval Number: 05026

Xyla, Contract Variation
Kent and Medway 057 November 2025
Classification: Official-Sensitive: Commercial

Contract/Variation Reference: CVO_057_November 2025

Proposed by: **NHS ENGLAND**

THIS VARIATION AGREEMENT is made on the date of the last signatory of this Variation Agreement
BETWEEN:

(1) **NHS England** of Wellington House, 133 – 155 Waterloo Road, London SE1 8UG (**“the Authority”**)

and

(2) **Pulse Healthcare Limited t/a Xyla** whose registered office Caledonia House, 223 Pentonville Road, London, N1 9NG (**“the Provider”**)

Each a **“Party”** and together referred to as **“the Parties”**.

Capitalised words and phrases in this Variation Agreement have the meanings given to them in the Contract (defined in Clause 1.1 of this Variation Agreement).

1. The Authority and the Provider entered into a contract entitled **“Type 2 Diabetes Path to Remission”** on 02/02/2024 (**“the Contract”**).
2. The Authority and the Provider have mutually agreed to vary the Contract as detailed below in Clause 5 of this Variation Agreement.
3. These Variations are designed to enable sufficient time for the transition and mobilisation of services under new ‘Healthier You’ contracts in 2026.
4. The Contract, including any previous Variations, shall remain effective and unaltered except as amended by this Variation Agreement.
5. The Contract Term shall be extended from 1st February 2026 to 31st March 2027 and in consideration of their respective obligations under the Contract (as varied by this Variation Agreement) the Parties have agreed the Variations set out below.
 - 5.1. The fourth bullet point in section 3.10 of Schedule 2A (Service Specification) of the Contract is replaced with the wording below:
 - "ensure that no Service User is invited to participate in the Service after 31 March 2027. The period from the Effective Date to this date is the "Intervention Period" for the purposes of Schedule 3A. The Provider agrees that the Commissioner is entitled to bring forward the end date of the Intervention Period by informing the Provider by email of a new expiry date of the Intervention Period. The Provider agrees that:
 - the Commissioner bringing forward the end date of the Intervention Period in this way does not require the Provider's consent;
 - where the Commissioner brings forward the end date of the Intervention Period in this way, it will inform the Provider of the new date at least 90 days before the amended end date of the Intervention Period.

Xyla, Contract Variation
Kent and Medway 057 November 2025
Classification: Official-Sensitive: Commercial

5.2. The following wording is added to the end of the second bullet point in section 3.10 of Schedule 2A (Service Specification) of the Contract:

- "Where, after 30 January 2026, the Provider invites Service Users to participate, the Intervention Cap will be increased by 300 from that date, with an indicative value of £281,401 (Exclusive of VAT)."

6. The Variation set out in this Variation Agreement will take effect on the date this Variation Agreement is made.

IN WITNESS OF WHICH the Parties have signed this Variation Agreement on the date(s) shown below:

Signed by [REDACTED] on behalf of **Pulse Healthcare Limited t/a Xyla**
Signed by: [REDACTED]
Full Name: [REDACTED]
Job Title/Role: [REDACTED]
Date Signed: 18/12/25

Signed by [REDACTED] on behalf of the **NHS ENGLAND:**
Signed by: [REDACTED]
Full Name: [REDACTED]
Job Title/Role: [REDACTED]
Date Signed: 18/12/2025